C R Bard Inc (BCR) : Findlay Park Partners Llp reduced its stake in C R Bard Inc by 16.16% during the most recent quarter end. The investment management company now holds a total of 1,660,000 shares of C R Bard Inc which is valued at $369,350,000 after selling 320,000 shares in C R Bard Inc , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.C R Bard Inc makes up approximately 4.06% of Findlay Park Partners Llp’s portfolio.
Other Hedge Funds, Including , Mycio Wealth Partners boosted its stake in BCR in the latest quarter, The investment management firm added 160 additional shares and now holds a total of 599 shares of C R Bard Inc which is valued at $133,278. C R Bard Inc makes up approx 0.02% of Mycio Wealth Partners’s portfolio.Global X Management Co boosted its stake in BCR in the latest quarter, The investment management firm added 329 additional shares and now holds a total of 656 shares of C R Bard Inc which is valued at $146,360. C R Bard Inc makes up approx 0.01% of Global X Management Co’s portfolio. Lsv Asset Management added BCR to its portfolio by purchasing 525 company shares during the most recent quarter which is valued at $116,823.Security National Trust Co boosted its stake in BCR in the latest quarter, The investment management firm added 340 additional shares and now holds a total of 6,970 shares of C R Bard Inc which is valued at $1,603,100. C R Bard Inc makes up approx 0.57% of Security National Trust Co’s portfolio.
C R Bard Inc opened for trading at $217.89 and hit $219.22 on the upside on Friday, eventually ending the session at $219.08, with a gain of 0.44% or 0.97 points. The heightened volatility saw the trading volume jump to 5,45,611 shares. Company has a market cap of $16,092 M.
On the company’s financial health, C R Bard Inc reported $2.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $2.17. The company had revenue of $873.50 million for the quarter, compared to analysts expectations of $847.53 million. The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.10 EPS.
Many Wall Street Analysts have commented on C R Bard Inc. Company shares were Reiterated by Deutsche Bank on Jul 27, 2016 to “Hold”, Firm has raised the Price Target to $ 240 from a previous price target of $234 .Company shares were Reiterated by Barclays on Jul 27, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 235 from a previous price target of $224 .C R Bard Inc was Downgraded by BofA/Merrill to ” Neutral” on Jul 8, 2016.
C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.